Related Experiment Video
Updated: Jun 3, 2025
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
8.0K
An Overview of Gaucher Disease
Daniela Anahí Méndez-Cobián1,2, Sandra Guzmán-Silahua1,3, Diana García-Hernández1,4
1Unidad de Investigación Epidemiológica y en Servicios de Salud, Centro Médico Nacional de Occidente Órgano de Operación Administrativa Desconcentrada Jalisco, Instituto Mexicano del Seguro Social, Guadalajara 44329, Jalisco, Mexico.
Diagnostics (Basel, Switzerland)
|January 8, 2025
Summary
Gaucher disease (GD) management in Mexico benefits from early diagnosis and enzyme replacement therapy (ERT). Further research is needed for neuropathic types and Mexican GD epidemiology to improve patient outcomes.
Area of Science:
- Genetics and rare diseases
- Metabolic disorders
- Hematology
Background:
- Gaucher disease (GD) is an autosomal recessive disorder caused by GBA1 gene mutations.
- Leads to glucocerebrosidase deficiency and glucocerebroside accumulation in macrophages.
- Primarily impacts liver, spleen, and bone marrow, with a focus on the Mexican population.
Purpose of the Study:
- Review GD epidemiology, clinical manifestations, and treatment in Mexico.
- Enhance early diagnosis and optimize treatment outcomes for Gaucher disease patients.
- Provide insights into the specific challenges and approaches within the Mexican context.
Main Methods:
- Comprehensive literature review methodology.
- Analysis of epidemiological data, clinical presentations, and therapeutic strategies.
- Inclusion of enzyme replacement therapy (ERT) and substrate reduction therapy (SRT).
Main Results:
- Early diagnosis and individualized treatment, especially ERT, significantly improve prognosis for Gaucher disease type 1.
- Current therapeutic approaches focus on managing symptoms and enzyme deficiencies.
- Highlights the need for population-specific data, particularly for Mexico.
Conclusions:
- Individualized treatment, primarily ERT, is crucial for favorable Gaucher disease prognosis.
- Further research is essential for neuropathic GD types and Mexican epidemiological data.
- Improved understanding and targeted therapies will enhance patient quality of life.
Related Concept Videos
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
01:15Parkinson's Disease: Overview
472
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
472
01:23Cystic Fibrosis: Pathogenesis
185
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
185
01:27Glucose Transporters
22.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K
01:20Inborn Errors of Metabolism
126
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
126
01:26Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444